

e-Appendix 1: Members of the Canadian Hypertension Education Program as at March 2005

- **Steering Committee:** N. Campbell (Chair), R. Feldman, R. Petrella, G. Taylor, S. Tobe, R. Touyz, D. Drouin
- **Executive Committee:** N. Campbell (Chair), R. Feldman, D. Drouin, S. Tobe, R. Touyz, F. McAlister
- **Evidence-Based Recommendations Task Force:** S. Tobe (Co-Chair), R. Touyz (Co-Chair)
 - **Central Review Committee:** F. McAlister (Chair), B. Hemmelgarn, N. Khan, R. Padwal
 - **Subgroups:**
 - **Lifestyle modification in hypertension:** R. Touyz (Chair), A. Logan, N. Gledhill, R. Petrella, N. Campbell
 - **Concordance strategies for patients:** C. Herbert (Chair), R. Feldman
 - **Pharmacotherapy for hypertensive patients with CVD:** S. Rabkin (Chair), M. Arnold, G. Moe, M. Hill
 - **Pharmacotherapy for hypertensive patients without compelling indications:** R. Lewanczuk (Chair), R. Herman, P. Hamet, G. Fodor, G. Carruthers, B. Culleton, J. deChamplain, G. Pylypchuk
 - **Endocrinological forms of hypertension:** E. Schiffrin (Chair)
 - **Renal and renovascular hypertension:** M. Lebel (Chair), S. Tobe, E. Burgess
 - **Hypertension and diabetes:** L. Leiter (Chair), C. Jones, P. Larochelle, R. Ogilvie, S. Tobe, R. Houlden
 - **Accurate measurement of BP:** C. Abbott (Chair), K. Mann
 - **Routine laboratory testing:** T. Wilson (Chair), B. Penner
 - **Follow-up of BP:** P. Bolli (Chair), G. Tremblay
 - **Self-measurement of BP:** D. McKay (Chair), A. Chockalingam
 - **Ambulatory BP monitoring:** M. Myers (Chair), S. Rabkin
 - **Echocardiography:** G. Honos (Chair)
 - **Global risk assessment:** S. Grover (Chair), G. Tremblay, A. Milot
 - **Librarian:** Angela Eady
- **Implementation Task Force:** D. Drouin (Chair), N. Campbell, R. Feldman, A. Milot, C. Repchinsky, T. Ruddy, G. Tremblay, B. Semchuk, J. Stone, E. Wilson, S. Chander, R. Petrella, R. Feldman (Ex-officio)
- **Outcomes Research Task Force:** N. Campbell (Chair), R. Brant, A. Chockalingam, B. Hemmelgarn, M. Hill, H. Johansen, N. Khan, F. McAlister, J. Onysko, H. Quan, Stephen Phillips, G. Taylor, K. Tu, E. Wilson, D. Drouin (Ex-officio), R. Feldman (Ex-officio)

Note: BP = blood pressure, CVD = cardiovascular disease.

e-Appendix 2: Industry sponsorship (in the form of unrestricted educational grants)

- Abbott Laboratories
- AstraZeneca Canada
- Bayer
- Biovail Pharmaceuticals Canada
- Boehringer Ingelheim (Canada)
- Bristol-Myers Squibb Canada
- Fournier Pharma
- Merck Frosst Canada
- Novartis Pharmaceuticals Canada
- Pfizer Canada
- Servier Canada
- Solvay Pharma